This session addresses the challenges of transcatheter interventions in severe mitral stenosis and mitral annular calcification. It highlights therapeutic innovations such as treating mitral stenosis with annular calcification, valve-in-MAC procedures, use of extra-large Myval valves, transatrial ViMAC approaches, and combined multivalve interventions in rheumatic heart disease.

Explore the integration of CT coronary angiography into catheterization laboratory practice through real-world studies assessing anatomical yield, diagnostic accuracy, and physiological assessments. The session highlights advancements in myocardial blood flow analysis and plaque characterization to improve ischemia detection and guide invasive angiography.

This session explores the complexities that arise when atrial septal closure procedures become challenging. It covers hybrid retrieval techniques for occluder devices, management of device-related complications mimicking infection, resolution of uncommon complications, and case studies including cryptogenic stroke management in athletes, highlighting procedural intricacies and solutions.

This session focuses on imaging-guided CTO PCI, presenting cases that illustrate the utility of OCT, CT, and IVUS for lesion assessment and procedural guidance. Topics include woven-like CTOs, double CTO evaluation, management of late stent malapposition, and strategies for navigating complex occlusions to optimize outcomes.

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.